(Br6) Re Entry
Payments companies reported to CMS as associated with (Br6) Re Entry. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with (Br6) Re Entry, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with (Br6) Re Entry
These are the largest totals companies reported as associated with (Br6) Re Entry. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Jose Suarez | Lubbock, TX | Interventional Cardiology | $97.04 |
| Jorge Salazar | Memphis, TN | Vascular & Interventional Radiology | $82.85 |
| Salil Joshi | Memphis, TN | Vascular & Interventional Radiology | $82.84 |
| Steve Hong | Dallas, TX | Vascular & Interventional Radiology | $62.47 |
| Tariq Yousuf | Sherman, TX | Internal Medicine | $53.61 |
| Naixin Kang | Miami, FL | Vascular Surgery | $37.75 |
| Piedad Zamora-Seymour | Miami, FL | Adult Health (Nurse Practitioner) | $37.75 |
| Kathy Gonzalez | Miami, FL | Vascular Surgery | $37.75 |
| Dylan Abeysekera | Miami, FL | $37.75 | |
| Leigh Ann Jenkins | Lubbock, TX | Cardiovascular Disease | $37.60 |
Prescribed (Br6) Re Entry?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.